Holy Name Hospital
Holy Name Hospital
Teaneck, New Jersey, United States32 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | pancreatic acinar cell carcinoma, pancreatic adenosquamous carcinoma, squamous cell carcinoma of pancreas | Recruiting | Phase 2 | 2026-10-08 | NCT04858334 | |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-10-08 | NCT03678025 | |
| Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | Digestive System Diseases, Digestive System Neoplasms, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, breast carcinoma, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, immune system disorder, immunoproliferative disorder, intestinal disorder, lung disorder, lung neoplasm, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-Hodgkin lymphoma, non-small cell lung carcinoma, primitive neuroectodermal tumor, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm | Recruiting | Not stated | 2026-10-07 | NCT06418204 | |
| NCI COVID-19 in Cancer Patients, NCCAPS Study | COVID-19, Coronaviridae Infections, Infections, Neoplasm Metastasis, Neoplastic Processes, Nidovirales infectious disease, Orthocoronavirinae infectious disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, lung disorder, neoplasm, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Not stated | 2026-10-07 | NCT04387656 | |
| Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer | invasive breast carcinoma | Active, not recruiting | Phase 2 | 2026-10-06 | NCT04001829 | |
| Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, castration-resistant prostate carcinoma, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2026-10-06 | NCT03419234 | |
| Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, invasive breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-10-02 | NCT02445391 | |
| Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy | invasive breast carcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT04379570 | |
| Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, anal margin squamous cell carcinoma, anus basaloid carcinoma, anus disorder, anus neoplasm, cloacogenic carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm | Active, not recruiting | Phase 3 | 2026-10-01 | NCT03233711 | |
| Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 2 | 2026-09-29 | NCT04175912 | |
| Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-25 | NCT05610163 | |
| A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Multiple Sclerosis, Primary Progressive, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 3 | 2026-09-17 | NCT04544449 | |
| CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | invasive breast carcinoma | Active, not recruiting | Phase 2 | 2026-09-14 | NCT04266249 | |
| Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials | Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm | Active, not recruiting | Early phase 1 | 2026-09-04 | NCT05108298 | |
| Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic adenosquamous carcinoma, pancreatic neoplasm | Active, not recruiting | Phase 3 | 2026-09-04 | NCT04340141 | |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-09-02 | NCT05879926 | |
| Breast Cancer WEight Loss Study (BWEL Study) | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast carcinoma in situ, breast disorder, breast neoplasm, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, invasive breast carcinoma, neoplasm, skin disorder, synchronous bilateral breast carcinoma | Active, not recruiting | Phase 3 | 2026-09-02 | NCT02750826 | |
| Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-08-31 | NCT01901094 | |
| A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 3 | 2026-07-29 | NCT05269004 | |
| Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Active, not recruiting | Phase 2 | 2026-07-10 | NCT04233866 | |
| T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | HER2 positive breast carcinoma, invasive breast carcinoma, synchronous bilateral breast carcinoma | Active, not recruiting | Phase 3 | 2026-06-15 | NCT04457596 | |
| Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | Carcinoma, Ductal, Carcinoma, Lobular, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast disorder, breast ductal adenocarcinoma, breast neoplasm, carcinoma, epithelial neoplasm, invasive ductal breast carcinoma, invasive lobular breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-06-05 | NCT01953588 | |
| Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Previously Treated Non-Small Cell Lung Cancer | Recruiting | Phase 2 / Phase 3 | 2026-05-18 | NCT03851445 | |
| Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-05-06 | NCT02488967 | |
| Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors | Malignant Solid Neoplasm | Recruiting | Not stated | 2026-05-05 | NCT04871542 |